Embryonic natural killer cell development and function

胚胎自然杀伤细胞的发育和功能

基本信息

  • 批准号:
    10661496
  • 负责人:
  • 金额:
    $ 57.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT The overall goal of our research is to understand the origin, development and function of embryonic Natural Killer (NK) cells. NK cells are innate immune system lymphocytes and a current target population for cell- based adoptive immunotherapies. However, NK cell therapy has been demonstrated to be effective in only a subset of patients, possibly due in part to the highly heterogeneous nature of NK cell subsets found across donors. In contrast, the generation of NK cells from human pluripotent stem cells (hPSCs) is a particularly exciting alternative, as it would eliminate genetic variability across donor sources, ensuring highly reproducible generation of anti-tumor NK cells. While NK cells in the adult are derived from hematopoietic stem cell (HSC)- derived lymphoid progenitors, the developmental origin of NK cells remains poorly understood. We have demonstrated that HSC-independent hematopoiesis occurs in multiple waves in the early murine embryo, including multipotential “erythro-myeloid progenitors” (EMP). Similarly, we have developed an in vitro hPSC stage-specific differentiation approach that recapitulates many aspects of embryonic hematopoietic development. Combining these systems, our preliminary parallel studies indicate that HSC-independent, “extra-embryonic” erythro-myeloid progenitors can generate NK cells, which are morphologically and functionally distinct from “intra-embryonic” hPSC-derived definitive progenitors, or neonatal donors. The focus of this proposal is to bring together expertise in mouse developmental biology and hPSC directed differentiation, as complementary model systems, to identify the origin(s) of embryonic NK cells, and their translational potential. We hypothesize that these fetal NK cells are a clinically-relevant source of NK cells, with robust antitumor capacity. We will test this hypothesis across three Specific Aims. In Aim 1, we will characterize the ontogenic origins of murine embryonic and hPSC-derived NK cells, establishing their lineage specification from a multipotential myeloid progenitor and the transcriptional regulatory programs. In Aim 2, we will establish the contribution of embryonic NK cells to the adult lymphocyte repertoire, and functionally characterize the adoptive transfer antitumor potential of HSC-independent NK cells. The successful completion of these studies will provide us with a more comprehensive understanding of mammalian hematopoietic development. This is of fundamental importance to our understanding of the development of the innate immune system and the in vitro generation of NK cells for a wide array of regenerative medicine applications, including anti-cancer therapy.

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CD1d expression demarcates CDX4+ hemogenic mesoderm with definitive hematopoietic potential.
  • DOI:
    10.1016/j.scr.2022.102808
  • 发表时间:
    2022-07
  • 期刊:
  • 影响因子:
    1.2
  • 作者:
    Creamer, J. Philip;Luff, Stephanie A.;Yu, Hao;Sturgeon, Christopher M.
  • 通讯作者:
    Sturgeon, Christopher M.
Yolk sac cell atlas reveals multiorgan functions during human early development.
  • DOI:
    10.1126/science.add7564
  • 发表时间:
    2023-08-18
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Goh I;Botting RA;Rose A;Webb S;Engelbert J;Gitton Y;Stephenson E;Quiroga Londoño M;Mather M;Mende N;Imaz-Rosshandler I;Yang L;Horsfall D;Basurto-Lozada D;Chipampe NJ;Rook V;Lee JTH;Ton ML;Keitley D;Mazin P;Vijayabaskar MS;Hannah R;Gambardella L;Green K;Ballereau S;Inoue M;Tuck E;Lorenzi V;Kwakwa K;Alsinet C;Olabi B;Miah M;Admane C;Popescu DM;Acres M;Dixon D;Ness T;Coulthard R;Lisgo S;Henderson DJ;Dann E;Suo C;Kinston SJ;Park JE;Polanski K;Marioni J;van Dongen S;Meyer KB;de Bruijn M;Palis J;Behjati S;Laurenti E;Wilson NK;Vento-Tormo R;Chédotal A;Bayraktar O;Roberts I;Jardine L;Göttgens B;Teichmann SA;Haniffa M
  • 通讯作者:
    Haniffa M
Haematopoietic stem and progenitor cell heterogeneity is inherited from the embryonic endothelium.
  • DOI:
    10.1038/s41556-023-01187-9
  • 发表时间:
    2023-08
  • 期刊:
  • 影响因子:
    21.3
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Palis其他文献

James Palis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Palis', 18)}}的其他基金

Embryonic natural killer cell development and function
胚胎自然杀伤细胞的发育和功能
  • 批准号:
    10328573
  • 财政年份:
    2021
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8829970
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
2013 Red Cells Gordon Research Conference & Gordon Research Seminar
2013 红细胞戈登研究会议
  • 批准号:
    8525933
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8694029
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    9043868
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8478982
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    9264520
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8685321
  • 财政年份:
    2012
  • 资助金额:
    $ 57.94万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8875051
  • 财政年份:
    2012
  • 资助金额:
    $ 57.94万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8417125
  • 财政年份:
    2012
  • 资助金额:
    $ 57.94万
  • 项目类别:

相似海外基金

Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
调节PD-1/PD-L1检查点促进肉瘤患者HER2 CAR T细胞的抗肿瘤活性
  • 批准号:
    10562836
  • 财政年份:
    2023
  • 资助金额:
    $ 57.94万
  • 项目类别:
“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
– NR4A1 和 NR4A2 的药理学靶向激活胶质母细胞瘤治疗反应 –
  • 批准号:
    10744524
  • 财政年份:
    2023
  • 资助金额:
    $ 57.94万
  • 项目类别:
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation
将来自免疫活性干细胞供体的疫苗诱导的免疫力转移作为抗病毒免疫疗法,以保护高危移植受者免受巨细胞病毒再激活
  • 批准号:
    10659635
  • 财政年份:
    2023
  • 资助金额:
    $ 57.94万
  • 项目类别:
Optimizing CAR T therapy via metabolic engineering for thetreatment of GBM
通过代谢工程优化 CAR T 疗法治疗 GBM
  • 批准号:
    10722922
  • 财政年份:
    2023
  • 资助金额:
    $ 57.94万
  • 项目类别:
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia
项目 4:现成的工程化脐带血自然杀伤细胞,用于治疗急性淋巴细胞白血病
  • 批准号:
    10931069
  • 财政年份:
    2023
  • 资助金额:
    $ 57.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了